Ovation and Coriell Life Sciences Partner to Streamline Genetic Reporting Workflows

Ovation.io, Inc. (Ovation), makers of the fastest-growing clinical laboratory information and commercialization platform, and Coriell Life Sciences, Inc., an innovative provider of clinical genetic reporting solutions, announced a partnership and platform integration designed to create a seamless ecosystem for sample and workflow management, genetic data interpretation, and external client communication. Initial offerings will focus on pharmacogenomics and women's health, with plans to rapidly expand into cancer genomics, infectious disease diagnosis, and other personalized medicine efforts.

“This partnership marks a significant advance in our mission to help diagnostic labs streamline their operations across many functional areas. With Coriell Life Sciences, we’re able to provide our customers with a comprehensive, cloud-based platform for the management of genomic data, genomic interpretation and reporting that presents only the most valuable and relevant clinical data. We’re helping to make precision medicine even more targeted and actionable,” said Barry Wark, Chief Executive Officer of Ovation. “This partnership will allow our customer labs to bring payors and providers the single most efficient resource for accurately determining drug efficacy across a patient’s often complex medication regimen.”

The deep API integration of the companies' respective cloud-based platforms enables Ovation and Coriell Life Sciences to provide end-to-end management of samples and results for multi-site and multi-institution projects.  Amongst the earliest pioneers to implement this platform is an organization sponsoring pharmacogenetic testing for tens of thousands of its beneficiaries, the first of many personalized medicine programs utilizing the platform.

“Our joint platform will enable providers to streamline their processes and analyze genetic data in a way we’ve never done before,” said Dr. Jeffrey Shaman, Director of Business Development for Coriell Life Sciences. “We are now able to leverage our clinical genetic reporting technology to not only manage the breadth of information obtained through genomic sequencing, but to better support individual and customized clinical laboratory technologies and assays, while also progressing clinical laboratories toward faster and more efficient commercialization.” 

The aim of personalized medicine and genetic biomarkers is to deliver the right treatment to the right patient from the start. Patients are often prescribed multiple medications with little consideration for adverse reactions that result from specific combinations. With precision medicine, risk factors affecting the safety profile of drug interactions, genetic metabolism, lifestyle, and diet conflicts are considered when tailoring medication regimens to each individual patient’s treatment plan. Patients and providers are armed with the best treatment plan up front that carries the least risk, while delivering the intended therapy, benefiting both the patient and the healthcare system.

Ovation and Coriell Life Sciences will leverage their technology partnership with additional partners to expand the combined platform into a central ecosystem.  This will enable clinical labs to manage their entire commercialization efforts right out-of-the-box and with considerably less implementation time and effort.

This article has been republished from materials provided by Ovation.io, Inc.. Note: material may have been edited for length and content. For further information, please contact the cited source.